Search Clinical Trials in the European Union

Duration
Visits
Efficacy phase (II)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
881-900 of 1,738 trials

Cognitive Disorders: BioFINDER 2 Study

We are investigating new imaging methods to better diagnose Alzheimer's disease in healthy older adults and those with early cognitive symptoms. The goal is to understand brain changes that may lead to dementia.

Dementia and Neurodegenerative Disorders>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesPartially RemoteInternal MedicineNeurology

B Cell Lymphoma: CAR20(NAP)-T Therapy

We are evaluating a new CAR-T cell therapy for patients with relapsed or refractory B cell lymphoma. The study aims to assess its safety and effectiveness in treating this condition.

Non-Hodgkin's LymphomaSafety phase (I)Efficacy phase (II)Oncology

Temozolomide for Non-enhancing Adult Brainstem Gliomas

We are studying the effects of Temozolomide chemotherapy in adults with specific types of brainstem gliomas. This trial aims to see how well it works for tumors that show an infiltrative pattern of growth.

Malignant GliomaBrain Stem Glioma>2 yearsEfficacy phase (II)NeurologyOncology

Baricitinib for Calcium Pyrophosphate Disease

We are studying whether Baricitinib can reduce inflammation and improve symptoms in people with calcium pyrophosphate dihydrate deposition disease. This trial will help us understand its effects on pain and inflammation.

Calcium Pyrophosphate Deposition Disease3-6 monthsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesInternal MedicineRheumatology

Tremelimumab Injection for Early-Stage Lung Cancer

We are studying a new injection method for delivering tremelimumab to patients with early-stage non-small cell lung cancer. The goal is to evaluate its safety and how well it works in the body.

Non-small cell lung cancer1-2 yearsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesOncologyPulmonology

Dermatomyositis: Baricitinib Treatment Study

We are studying whether baricitinib can help patients with dermatomyositis improve without using steroids. This trial compares its effects to a placebo while providing usual care.

Dermatomyositis>2 yearsEfficacy phase (II)Confirmation phase (III)≤5 visitsStandard MedicinesDermatologyRheumatology

Pancreatic Cancer: FOLFOX vs. Gemcitabine

We are comparing two chemotherapy treatments, FOLFOX and gemcitabine, for patients with advanced pancreatic cancer who cannot tolerate a stronger regimen. The goal is to see which treatment works better and is safer for these patients.

Pancreatic Cancer>2 yearsEfficacy phase (II)Confirmation phase (III)No PlaceboStandard MedicinesOncology

Acromegaly: Paltusotine Treatment Study

We are studying the long-term safety and effectiveness of paltusotine for people with acromegaly. This research aims to improve treatment options for managing this condition.

Acromegaly>2 yearsEfficacy phase (II)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteEndocrinology

Carcinoid Syndrome: Paltusotine Treatment Study

We are evaluating the safety and how the body processes different doses of paltusotine in people with carcinoid syndrome. This study aims to ensure the treatment is safe and well-tolerated.

Carcinoid Syndrome3-6 monthsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteGastroenterologyOncology

Painful Venous Malformations: Apixaban Study

We are investigating whether apixaban can help reduce pain and improve quality of life for patients with painful venous malformations. The study also looks at safety and how the medication affects blood clotting.

Venous Malformation1-2 yearsEfficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesHematologyInternal Medicine

Diffuse Cutaneous Systemic Sclerosis: Ianalumab Study

We are testing a new medication, ianalumab, for people with diffuse cutaneous systemic sclerosis. The goal is to see if it improves symptoms and lung function compared to a placebo.

Systemic Scleroderma>2 yearsEfficacy phase (II)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteRheumatology

Pasireotide for Synovial Sarcoma and Desmoplastic Small Round Cell Tumor

We are studying whether pasireotide can help patients with specific cancers live longer without their disease progressing. This trial focuses on those with synovial sarcoma and desmoplastic small round cell tumor.

Locally Advanced or Metastatic Synovial SarcomaLocally Advanced or Metastatic Desmoplastic Small Round Cell Tumor>2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteOncology

Knee Osteoarthritis: Intra-Articular Clodronate Study

We are investigating whether different doses of clodronate can help reduce knee pain and improve function in people with painful knee osteoarthritis. The study will also monitor safety and tolerability of the treatment.

Knee Osteoarthritis>2 yearsEfficacy phase (II)Confirmation phase (III)6-10 visitsPost-Trial Drug AccessStandard MedicinesOrthopedics and TraumatologyRheumatology

Dapagliflozin for Decompensated Liver Cirrhosis

We are studying whether dapagliflozin is safe and effective for patients with decompensated liver cirrhosis compared to standard treatments. The trial also looks at how it may affect quality of life and various health markers.

Decompensated Liver Cirrhosis6-12 monthsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesHepatologyInternal Medicine

Non-Hodgkin Lymphoma: New CAR T-Cell Therapy Study

We are comparing a new point-of-care CAR T-cell treatment to a standard commercial option for patients with relapsed or refractory Non-Hodgkin Lymphoma. The goal is to see if the new therapy can improve survival and safety outcomes.

Relapsed/Refractory Non-Hodgkin Lymphoma>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesOncology

Alpha-1 Antitrypsin Deficiency: WVE-006 Treatment

We are testing a new treatment called WVE-006 for people with Pi*ZZ Alpha-1 Antitrypsin Deficiency. The study aims to evaluate its safety and how the body responds to it.

Alpha-1 Antitrypsin Deficiency6-12 monthsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesEndocrinologyGastroenterologyHepatologyInternal MedicinePulmonology

Mantle Cell Lymphoma: Pirtobrutinib and Rituximab Study

We are evaluating a new treatment combining pirtobrutinib and rituximab for patients with indolent Mantle Cell Lymphoma. The study aims to determine its effectiveness and safety compared to standard therapies.

Mantle Cell Lymphoma1-2 yearsEfficacy phase (II)16-20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesHematologyOncology

Idiopathic Bile Acid Diarrhea: Colesevelam Hydrochloride Tablet

We are studying a new tablet for patients with idiopathic bile acid diarrhea to see if it improves stool consistency compared to a placebo. The trial will also evaluate the safety and tolerability of this treatment.

Bile Acid Diarrhoea≤3 monthsEfficacy phase (II)≤5 visitsInvestigational MedicinesGastroenterologyInternal Medicine

Short Bowel Syndrome: Crofelemer Study

We are testing crofelemer to see if it helps adults with Short Bowel Syndrome and Intestinal Failure manage their symptoms better. The study will assess its safety and effectiveness compared to a placebo.

Short Bowel Syndrome and Intestinal Failure6-12 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesGastroenterologyInternal Medicine

Atezolizumab for Muscle-Invasive Bladder Cancer

We are studying whether atezolizumab can help patients with muscle-invasive bladder cancer who cannot have surgery after chemo-radiotherapy. The trial looks at how well it works and its impact on patients' quality of life.

Muscle-Invasive Bladder Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncologyUrology